RBM 006
Alternative Names: RBM-006Latest Information Update: 28 Sep 2024
At a glance
- Originator Ribomic
- Class Antifibrotics; Nucleotide aptamers; Skin disorder therapies
- Mechanism of Action ENPP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
- Discontinued Hepatic fibrosis; Scleroderma
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Japan (Parenteral)
- 15 Jul 2021 Preclinical development for Idiopathic pulmonary fibrosis is ongoing Japan (Parenteral) (Ribomic pipeline, July 2021)
- 15 Jul 2021 Discontinued - Preclinical for Hepatic fibrosis in Japan (Parenteral) (Ribomic pipeline, July 2021)